Direct inhibition of pain facilitatory neurons in the rostral ventromedial medulla (RVM) is one mechanism by which mu opioid receptor (MOPr) agonists are proposed to produce antinociception. The antinociceptive and anti-hyperalgesic effects of the MOPr agonist DAMGO are enhanced after intraplantar injection of complete Freund's adjuvant (CFA). This study therefore examined whether CFA treatment similarly enhanced the ability of DAMGO to induce outward currents in spinally projecting RVM neurons. It further examined whether the electrophysiological properties of RVM neurons are altered by CFA treatment. Whole-cell patch clamp recordings were made from three types of serotonergic as well as nonserotonergic spinally projecting RVM neurons obtained from control rats and rats 4 h or four days after CFA. Persistent, but not acute inflammatory nociception increased the percentage of Type 2 non-serotonergic neurons that responded to DAMGO from 17% to 57% and the percentage of Type 3 serotonergic neurons that responded to DAMGO from 5% to 55%. These same two populations of RVM neurons exhibited significant differences in their passive membrane properties or spontaneous discharge rate. The outward currents produced by the GABA B receptor agonist baclofen were not enhanced, suggesting that the enhancement does not reflect global changes in levels of G i/o or activity of G-protein regulated inwardly rectifying potassium channels. These results provide a cellular basis for the enhanced anti-hyperalgesic and antinociceptive effects of MOPr agonists under conditions of persistent inflammatory nociception. These results also provide intriguing, albeit indirect, evidence for two different populations of pain facilitatory neurons in the RVM. Ó
a b s t r a c t
Direct inhibition of pain facilitatory neurons in the rostral ventromedial medulla (RVM) is one mechanism by which mu opioid receptor (MOPr) agonists are proposed to produce antinociception. The antinociceptive and anti-hyperalgesic effects of the MOPr agonist DAMGO are enhanced after intraplantar injection of complete Freund's adjuvant (CFA). This study therefore examined whether CFA treatment similarly enhanced the ability of DAMGO to induce outward currents in spinally projecting RVM neurons. It further examined whether the electrophysiological properties of RVM neurons are altered by CFA treatment. Whole-cell patch clamp recordings were made from three types of serotonergic as well as nonserotonergic spinally projecting RVM neurons obtained from control rats and rats 4 h or four days after CFA. Persistent, but not acute inflammatory nociception increased the percentage of Type 2 non-serotonergic neurons that responded to DAMGO from 17% to 57% and the percentage of Type 3 serotonergic neurons that responded to DAMGO from 5% to 55%. These same two populations of RVM neurons exhibited significant differences in their passive membrane properties or spontaneous discharge rate. The outward currents produced by the GABA B receptor agonist baclofen were not enhanced, suggesting that the enhancement does not reflect global changes in levels of G i/o or activity of G-protein regulated inwardly rectifying potassium channels. These results provide a cellular basis for the enhanced anti-hyperalgesic and antinociceptive effects of MOPr agonists under conditions of persistent inflammatory nociception. These results also provide intriguing, albeit indirect, evidence for two different populations of pain facilitatory neurons in the RVM.
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Introduction
Neurons in the nucleus raphe magnus and the adjacent nucleus reticularis gigantocellularis pars a, collectively termed the rostral ventromedial medulla (RVM), give rise to bulbospinal pathways that can either facilitate or suppress sensory transmission in the dorsal horn. Peripheral injury leads to sustained time-dependent changes in the pharmacology and physiology of these neurons, and in the balance of activity in bulbospinal pain facilitatory and inhibitory pathways. These changes have largely been inferred from findings that peripheral inflammatory injury causes a timedependent enhancement of the antinociceptive and anti-hyperalgesic effects of opioid [23, 24, 41 [3, 16, 27, 39] . However, technical limitations preclude an analysis of how injury alters the properties of these neurons and hinder determination of their axonal projections. None of these studies have addressed which populations of neurons mediate injury-induced changes in the potency and efficacy of drugs in the RVM. The first aim of the present study was to determine whether acute or persistent inflammatory nociception altered the passive membrane, action potential and discharge properties of any of the different types of spinally projecting RVM neurons. Whole-cell patch clamp recordings were made from different types of serotonergic and non-serotonergic spinally projecting RVM neurons [50] in brainstem slices from three different treatment groups: control (naïve or saline-treated), acute inflammatory injury, and persistent inflammatory injury produced by injection of complete Freund's adjuvant (CFA). The second aim was to determine which population(s) of neurons may mediate the enhanced antinociceptive and anti-hyperalgesic effects of the mu opioid receptor ( 
